A Phase III Randomized Trial Comparing High Dose Interferon To Mk-3475 (Pembrolizumab) In Patients With High Risk Resected Melanoma.
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Type of Study: Drug
the purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment with interferon alfa-2b. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or wors
Criteria:
To Be Eligible To Participate, Patients Must Have Been Diagnosed With Melanoma, Which Although It Ha
Keywords:
Resected, Skin Cancer, S1404, Cancer, Melanoma
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu